#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adult T-cell lymphoma/leukaemia refractory KBG syndrome Loeys-Dietz syndrome Salivary gland cancer Myotonia Myotonic dystrophy Mitochondrial encephalomyopathy Rhabdoid tumour Aspergillus infection Retinopathy proliferative Acquired haemophilia Multiple system atrophy Thalassaemia beta Oesophageal squamous cell carcinoma stage II Epilepsy with myoclonic-atonic seizures More trials…

    Learn about Rare Diseases

    Brain stem glioma Rhabdoid tumour – Life with Disease Hypereosinophilic syndrome – Trials in Disease Biotinidase deficiency – Diagnostics Aicardi-Goutieres syndrome Mucopolysaccharidosis – Treatment Erdheim-Chester disease – Life with Disease Primary hyperoxaluria – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Trials in Disease Angiosarcoma recurrent – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Kbp-336 Certolizumab Pegol Vinflunine Daridorexant Ngi226 Interferon Gamma RLY-2608 Pasireotide Diaspartate GSKVX000000030810 Vobramitamab Duocarmazine Phleum Pratense Odm-208 Umeclidinium Bromide Clavulanic Acid Omp65 Alendronic Acid Rbd1016 Phenobarbital Azilsartan Medoxomil Specific Nucleic Acid Sna-Papi More therapies…

    Learn about Your Condition

    Pelizaeus-Merzbacher disease Metastases to biliary tract Hypotransferrinaemia Monogenic diabetes Gender dysphoria Frontotemporal dementia Colorectal cancer stage IV Labour pain Angiopathy Neurogenic bladder Haemorrhage Vertigo Peritoneal neoplasm Haematological infection Neuroendocrine tumour More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

PIK3CA related overgrowth spectrum

  • Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

    Recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • Alpelisib
    Austria Belgium France Germany Italy The Netherlands +1

  • Study of RLY-2608 for Adults and Children with PIK3CA-Related Overgrowth and Malformations

    Recruiting

    2 1 1
    Investigated Diseases:
    • Lymphatic malformation
    • PIK3CA-activated mutation
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • RLY-2608
    Belgium France Germany Ireland Italy Norway +1

  • Study on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome

    Recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    Investigated Drugs:
    • Alpelisib
    France

  • Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

    Not recruiting

    2 1
    Investigated Drugs:
    • Alpelisib
    France Germany Italy The Netherlands Norway Spain

  • Study on the Long-Term Safety of Alpelisib for Patients with PIK3CA-Related Overgrowth Spectrum (PROS)

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Alpelisib
    France Ireland Spain

  • Long-term Safety Study of Miransertib for Patients with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome

    Not recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    • Proteus syndrome
    Investigated Drugs:
    • Miransertib
    Italy

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!